# Kenvue Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Kenvue Inc.). ## Overview Kenvue Inc. is a consumer health company built around everyday self-care, skin health, and essential health products sold under brands such as Tylenol, Listerine, Neutrogena, BAND-AID, Aveeno, Johnson’s, Nicorette, and Zyrtec. The company combines consumer marketing, scientific claims, and healthcare-professional trust to sell over-the-counter medicines, oral care, skin care, and personal care products in more than 165 countries. ## Products & services • Over-the-counter pain relief and allergy care • Oral care products, including mouthwash • Skin health and beauty products • Baby and personal care products • Wound care and first-aid products • Smoking cessation products - **Self Care** (41%) — Includes OTC medicines and consumer health products for pain, allergy, cough/cold, and smoking cessation. - **Skin Health and Beauty** (28%) — Includes facial care, body care, and dermatologist-recommended skin brands such as Neutrogena and Aveeno. - **Essential Health** (31%) — Includes oral care, baby care, and wound care products used in daily routines and basic household care. - Over-the-counter pain relief and allergy care - Oral care products, including mouthwash - Skin health and beauty products - Baby and personal care products - Wound care and first-aid products - Smoking cessation products ## Customers Kenvue sells primarily through retail and consumer health channels to households that buy trusted, repeat-use products for everyday care. Its customers also include large-format retailers, pharmacy chains, and e-commerce platforms that use bargaining power to negotiate pricing, trade support, and promotional terms. Demand is driven by brand trust, scientific credibility, and convenience rather than complex installation or service requirements. - **Mass retail and pharmacy channels** (primary) — Buy Tylenol, Listerine, Neutrogena, and other staples for broad consumer resale and shelf traffic. - **Household consumers** (primary) — Purchase everyday care products for pain relief, oral care, skin care, baby care, and first aid. - **E-commerce and digital shoppers** (secondary) — Buy through online marketplaces and direct digital channels where search, reviews, and convenience matter. - **Healthcare-influenced consumers** (secondary) — Choose products such as Nicorette, Zyrtec, and Tylenol based on efficacy and professional recommendation. - Households buying trusted OTC and personal care brands - Retailers and pharmacy chains seeking high-turn consumer staples - E-commerce platforms and omnichannel marketplaces - Customers that negotiate trade promotions, discounts, and media support - Healthcare-influenced buyers seeking science-backed brands ## Geography Kenvue operates globally across North America, APAC, EMEA, and LATAM, with products marketed in more than 165 countries. The company’s manufacturing and supply chain are described as globally balanced and purpose-built to shift resources across regions, which helps it manage retailer demand swings, shipping timing, and local consumer trends. China is specifically called out in the reports as a market where changing shopping patterns and consumer sentiment have affected performance in skin health. - **North America** (45%) — Estimated from company disclosure; no explicit regional revenue table provided. - **APAC** (20%) — Estimated from company disclosure; includes China exposure noted in filings. - **EMEA** (20%) — Estimated from company disclosure. - **LATAM** (15%) — Estimated from company disclosure. - Sales span North America, APAC, EMEA, and LATAM - Products are marketed in more than 165 countries - Global manufacturing footprint supports supply flexibility - China demand and shopping patterns have affected skin health - U.S. retailer inventory management has impacted volumes ## Strategy Kenvue is focused on transforming into a more efficient, digitally enabled consumer health company while improving execution and profitability. Management is using restructuring, shared services, and supply-chain optimization to fund brand investment, strengthen commercial capabilities, and support sustainable growth. In July 2025, the board also launched a strategic review of alternatives, including portfolio optimization, to unlock value. - **Operational transformation and cost reduction** (short-term) — Lower overhead and improve margins so more cash can be reinvested in brands and capabilities. - **Digital and commercial capability building** (medium-term) — Better consumer targeting and e-commerce execution are needed in a more fragmented retail environment. - **Portfolio and strategic review** (short-term) — Portfolio optimization may improve growth quality and unlock value across brands and categories. - Use restructuring to lower cost and improve operating efficiency - Invest behind core brands and consumer-facing innovation - Expand digital marketing, e-commerce, and precision targeting - Optimize portfolio and execution through strategic review - Modernize systems and supply chain after separation from J&J ## Risks Kenvue faces pressure from powerful retailers, changing consumer preferences, and intense competition from CPG, pharma, private label, and niche brands. Its transformation also creates execution risk through restructuring, IT modernization, cybersecurity exposure, and dependence on third parties for manufacturing and supply. In addition, product quality, regulatory compliance, and litigation remain important because the company sells health-related products with consumer safety implications. - **Retail concentration and bargaining pressure** [high] — Large customers and buying alliances can demand more trade promotions, media support, and discounts, reducing profitability. - **Consumer preference and demand volatility** [high] — The company depends on fast response to changing shopping patterns, seasonality, and regional trends. - **Supply chain and third-party manufacturing dependence** [high] — Kenvue relies on external partners and a global network, which reduces direct control over quality and continuity. - **Cybersecurity and technology systems disruption** [high] — Digital strategy and third-party integrations increase exposure to breaches, outages, and data misuse. - **Regulatory, litigation, and product safety exposure** [high] — Consumer health products face FDA oversight, compliance scrutiny, and potential claims tied to safety or labeling. - Retailers and alliances can demand higher trade spend and discounts - Consumer preferences shift quickly across regions and channels - Manufacturing or supplier disruptions can interrupt product supply - Cybersecurity and data risks rise as digital operations expand - Product quality, counterfeit risk, and regulation can damage trust ## Accounting Kenvue recognizes product revenue at a point in time when control transfers, and net sales are reduced by trade promotions, rebates, discounts, and expected returns. Reported results are also affected by restructuring charges, impairment testing, and estimates for variable consideration, which can move margins and comparability across periods. The company has disclosed significant impairment charges tied to Dr.Ci:Labo and other assets, showing how strategy changes and market shifts can quickly affect carrying values. - **Revenue recognition and variable consideration** — Can shift reported revenue and gross margin when estimates change - **Seasonality and shipment timing** — Affects comparability of quarterly sales and inventory levels - **Goodwill and intangible asset impairment** — Can create large non-cash charges and signal weaker category outlook - **Restructuring and operating model optimization** — Impacts operating expenses and near-term earnings - **Tax and litigation contingencies** — Can affect tax expense, reserves, and cash flows - Revenue is recognized at shipment or receipt, depending on contract terms - Net sales are reduced by coupons, rebates, discounts, and returns estimates - Seasonality affects quarter-to-quarter comparability in allergy and cold products - Impairment testing can create large non-cash charges on brands and software - Restructuring and transformation costs affect operating income and cash flow --- *Last updated: 2026-08-11T04:03:56.228997+00:00*